These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15061847)

  • 1. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.
    Euvrard S; Ulrich C; Lefrancois N
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):628-33. PubMed ID: 15061847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
    Leblanc KG; Hughes MP; Sheehan DJ
    Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients.
    Ulrich C; Schmook T; Sachse MM; Sterry W; Stockfleth E
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):622-7. PubMed ID: 15061846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
    J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic strategies for chemoprevention of skin cancers in transplant recipients.
    Kovach BT; Sams HH; Stasko T
    Clin Transplant; 2005 Dec; 19(6):726-34. PubMed ID: 16313317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T; Kreis H; Friend P
    Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing the risk of posttransplant malignancy.
    Campistol JM
    Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary immunosuppressants do not enhance UV-induced skin carcinogenesis, and reveal discordance between p53-mutant early clones and carcinomas.
    Voskamp P; Bodmann CA; Koehl GE; Rebel HG; Van Olderen MG; Gaumann A; El Ghalbzouri A; Tensen CP; Bavinck JN; Willemze R; Geissler EK; De Gruijl FR
    Cancer Prev Res (Phila); 2013 Feb; 6(2):129-38. PubMed ID: 23233735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cutaneous complications after organ transplantation].
    Gjersvik PJ
    Tidsskr Nor Laegeforen; 1999 Oct; 119(25):3789-92. PubMed ID: 10574059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair.
    Kuschal C; Thoms KM; Schubert S; Schäfer A; Boeckmann L; Schön MP; Emmert S
    Exp Dermatol; 2012 Jan; 21(1):2-6. PubMed ID: 22151386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting malignancy in organ transplant recipients.
    Geissler EK
    Transplant Proc; 2009; 41(6 Suppl):S9-12. PubMed ID: 19651298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients.
    Perera GK; Child FJ; Heaton N; O'Grady J; Higgins EM
    Br J Dermatol; 2006 May; 154(5):868-72. PubMed ID: 16634888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
    Rival-Tringali AL; Euvrard S; Decullier E; Claudy A; Faure M; Kanitakis J
    Anticancer Res; 2009 Jun; 29(6):1927-32. PubMed ID: 19528449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A; Schlitt HJ; Geissler EK
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin cancers following pediatric organ transplantation.
    Euvrard S; Kanitakis J; Cochat P; Claudy A
    Dermatol Surg; 2004 Apr; 30(4 Pt 2):616-21. PubMed ID: 15061845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.